MSP/P/AS; MF; ANRP ArrêtéArrêté N° 000315/MSP/P/AS/MF du 29 mars 2023
Currentness under review. Whether this instrument remains applicable is under review. Consult the later instruments and source context below before relying on it.
Arrêté N° 000315/MSP/P/AS/MF du 29 mars 2023 is the official MSP/P/AS; MF; ANRP identifier for “Arrêté fixant les montants dus au titre des redevances et autres services rendus par l’Agence Nigérienne de Réglementation du secteur Pharmaceutique (ANRP)”. Arrêté N° 000315/MSP/P/AS/MF du 29 mars 2023 is the official identifier MSP/P/AS; MF; ANRP uses for this instrument.
- Instrument
- Arrêté
- Full name
- Arrêté N° 000315/MSP/P/AS/MF du 29 mars 2023
- Category
- Registration
- Source publication
- French
- Readable HTML
- 1 language version
- Published
- —
- Effective
- —
Open a language version
Each version has stable passage anchors for direct citations and highlighting. The readable text is generated from an authority source and does not replace the legally controlling publication.
Arrêté fixant les montants dus au titre des redevances et autres services rendus par l’Agence Nigérienne de Réglementation du secteur Pharmaceutique (ANRP)
Selected physical pages 1–4 and 8–9 of the 13-page joint Health/Finance fee order dated 29 March 2023: complete general Articles 1–9, signatures and the complete MD/IVD marketing-authorisation fee row across two pages. Printed CFA amounts for devices from other countries are 300,000 initial, 300,000 major variation, 30,000 minor variation and 150,000 renewal; the UEMOA/CEDEAO row is 150,000, 150,000, 15,000 and 75,000. Article 7 permits later Board deliberations to change fees; these amounts are not claimed to be current. Article 8 expressly names earlier instruments 254/2013 and 0095/2020, without inventing catalogue targets. Pages 5–7 and 10–13 are excluded from this plan.
Arrêté N° 000315/MSP/P/AS/MF du 29 mars 2023 is the official identifier MSP/P/AS; MF; ANRP uses for this instrument. Always confirm the current consolidated text and transition provisions with the official source before filing.